Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin® class, a novel class of antimicrobial agents that fight infections by disrupting microbial membranes. It develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers. Lakewood-Amedex Biotherapeutics, Inc. was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June, 2025. The company was incorporated in 2006 and is headquartered in University Park, Florida.